Tuesday, June 6, 2017
23andMe, a personal genetics company, has announced a new grant from the NIH, for the creation of a genetic resource for health research in African Americans that could improve the understanding of diseases in minority populations.
23andMe launched its new Genotyping Services for Research (GSR) platform, providing scientists with an end-to-end service to incorporate genetic information into their studies.
23andMe, a personal genetics company, has appointed Dean Schorno, CPA, as chief financial officer and head of operations. He will oversee 23andMe’s global financial and clinical laboratory operations. Schorno brings a wealth of experience to the job, most recently working as chief financial officer of Adaptive Biotechnologies.
The Pulse on Global Trials by Matthew Howes
How you see the world depends on where you are. From one side of a room, the shadow of a cylinder may appear as a square; from the other side, a circle. Each perspective is true to the observer, but the truth is that both are correct.
23andMe, a personal genetics company based in Mountain View, Calif., has launched the Lupus Research Study in collaboration with Pfizer. The companies aim to enroll 5,000 individuals with systemic lupus erythematosus, more commonly known as lupus, into the study to help better understand the genetics of lupus. The effort also is in collaboration with the Lupus Research Institute and in concert with Lupus Awareness Month in May.
23andMe, a personal genetics company based in Mountain View, Calif., has created a new therapeutics group and has named Richard Scheller, Ph.D., to lead it as chief science officer and head of therapeutics. Scheller retired in December 2014 from a 14-year career at Genentech, where he was executive vice president of research and early development.
Having endured a 2013 FDA ban on selling the part of its $99 personal genome service that provided health-related results, 23andMe has come back strong with a new business strategy that involves more than a dozen partnerships with major biopharmaceutical companies.
23andMe, a privately held personal genomics and biotechnology company based in Mountain View, Calif., has inked an agreement with Genentech, a member of the Roche Group, to generate whole genome sequencing data for approximately 3,000 people in 23andMe’s Parkinson’s disease community. The goal of the collaboration is to identify new therapeutic targets for treating Parkinson’s disease.
23andMe, a California-based personal genetics company, and Pfizer have inked a research agreement in which the companies aim to enroll 10,000 people with inflammatory bowel disease (IBD) in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD.